SINTX Q3 Revenue Jumps Tenfold to $2.2M, Net Loss Halved
SINT sits 24% above its 52-week low of $1.4.
Summary
SINTX confirmed the $2.2 million Q3 revenue it pre-announced on October 1, but the full filing adds the numbers that matter: gross profit of $1.4 million at a 62% margin versus 45% a year ago, and a net loss cut 55% to $1.6 million from $3.5 million. Operating expenses fell 13% to $3.0 million, so the revenue jump is dropping through to the bottom line rather than being eaten by spending. The company ended the quarter with $2.0 million in cash and then pulled in another $2.0 million from 941,423 Class B warrants exercised at $2.14, which eases near-term funding pressure but leaves a very thin balance sheet against a $6.6 million nine-month burn. Commercial traction is the story to track: initial sales of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System have started, and large-animal studies on silicon nitride-treated wound care textiles are due in the first quarter of 2027.
At the time of this announcement, SINT was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $1.40 to $4.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.